Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (3): 255-262.doi: 10.12092/j.issn.1009-2501.2018.03.003

Previous Articles     Next Articles

Protective effects of Astragaloside Ⅳ on early kidney damage in diabetes mellitus rats and its mechanisms

LI Zhuqing 1, JU Yinghui 1, CHEN Qingqing 1, MA Keke 1, LI Weiping 1,2   

  1. 1 Department of Pharmacology, Anhui Medical University, Hefei 230032, Anhui, China; 2 Anqing Medical and Pharmaceutical College, Anqing 246052, Anhui, China
  • Received:2017-09-14 Revised:2017-12-19 Online:2018-03-26 Published:2018-03-28

Abstract:

AIM: To study the effects of Astragaloside Ⅳ (AS-Ⅳ) on early kidney damage and the mechanisms in diabetes mellitus rats induced by Streptozotocin (STZ).  METHODS: The diabetic rats model was established by intraperitoneal injection with STZ (55 mg/kg) and the model rats were randomly divided into model group,AS-Ⅳ (20, 40, 80 mg/kg) group. After 8 weeks of administration, body weight, blood glucose, 24 hours urinary protein excretion rate (24 h UAER), the level of serum creatinine (Scr), urea nitrogen (BUN) , serum SOD, GSH-Px activity and MDA content were measured. HE and PAS staining were used to observe renal histopathology and Western blot was used to detect the expression of TGF-β1, Nrf2 and HO-1.RESULTS:Compared with control group, the blood glucose, kidney index, MDA content and the level of Scr, BUN, 24 h UAER and expression of TGF-β1, total protein of Nrf2 and nucleus protein of Nrf2 increased significantly and the serum SOD and GSH-Px activity decreased significantly in diabetes mellitus model group. Compared with model group, AS-Ⅳ(40, 80 mg/kg) group could decrease MDA content , the level of Scr, BUN, 24 h UAER and increase serum SOD and GSH-Px activities, expression of TGF-β1 was decreased by AS-Ⅳ(80 mg/kg) group, expression of total Nrf2, nucleus Nrf2 and HO-1 were increased by AS-Ⅳ(80 mg/kg) group.CONCLUSION:AS-Ⅳ can inhibit renal oxidative stress injury. The meachanism may be related to increasing the serum antioxidant activity and reducing the expression of TGF-β1, activation of Nrf2 pathway, upregulating the expression of antioxidative protein in HO-1.

Key words: diabetes mellitus, astragaloside Ⅳ, TGF-β1, Nrf2

CLC Number: